Teriparatide treatment increases Hounsfield units in the lumbar spine out of proportion to DEXA changes

Presented at the 2019 AANS/CNS Joint Section on Disorders of the Spine and Peripheral Nerves

Restricted access

OBJECTIVE

The authors sought to assess whether Hounsfield units (HU) increase following teriparatide treatment and to compare HU increases with changes in bone mineral density (BMD) as measured by dual-energy x-ray absorptiometry (DEXA).

METHODS

A retrospective chart review was performed from 1997 to 2018 across all campuses at our institution. The authors identified patients who had been treated with at least 6 months of teriparatide and compared HU and BMD as measured on DEXA scans before and after treatment.

RESULTS

Fifty-two patients were identified for analysis (46 women and 6 men, average age 67 years) who underwent an average of 20.9 ± 6.5 months of teriparatide therapy. The mean ± standard deviation HU increase throughout the lumbar spine (L1–4) was from 109.8 ± 53 to 133.9 ± 61 HU (+22%, 95% CI 1.2–46, p value = 0.039). Based on DEXA results, lumbar spine BMD increased from 0.85 to 0.93 g/cm2 (+9%, p value = 0.044). Lumbar spine T-scores improved from −2.4 ± 1.5 to −1.7 ± 1.5 (p value = 0.03). Average femoral neck T-scores improved from −2.5 ± 1.1 to −2.3 ± 1.0 (p value = 0.31).

CONCLUSIONS

Teriparatide treatment increased both HU and BMD on DEXA in the lumbar spine, without a change in femoral BMD. The 22% improvement in HU surpassed the 9% improvement determined with DEXA. These results support some surgeons’ subjective sense that intraoperative bone quality following teriparatide treatment is better than indicated by DEXA results. To the authors’ knowledge, this is the first study demonstrating an increase in HU with teriparatide treatment.

ABBREVIATIONS BMD = bone mineral density; Cr = creatinine; DEXA = dual-energy x-ray absorptiometry; HU = Hounsfield units; ROI = region of interest.
Article Information

Contributor Notes

Correspondence Benjamin D. Elder: Mayo Clinic, Rochester, MN. elder.benjamin@mayo.edu.INCLUDE WHEN CITING Published online October 18, 2019; DOI: 10.3171/2019.7.SPINE19654.Disclosures Dr. Fogelson reports being a consultant for Medtronic; Dr. Larson reports being a consultant for Medtronic and Zimmer; Dr. Currier reports receiving royalties for a chapter in UpToDate from DePuy Synthes, Zimmer Biomet, and AOSpine North America and direct stock ownership in Tenex and Wolters Kluwer; and Dr. Anderson reports direct stock ownership and being a consultant for Titan Surgical, being a consultant for Globus, and receiving royalties from Regeneration Technologies, Inc.
Headings
References
  • 1

    Fischer CRHanson GEller MLehman RA: A systematic review of treatment strategies for degenerative lumbar spine fusion surgery in patients with osteoporosis. Geriatr Orthop Surg Rehabil 7:1881962016

    • Search Google Scholar
    • Export Citation
  • 2

    Genant HKEngelke KBolognese MAMautalen CBrown JPRecknor C: Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res 32:1811872017

    • Search Google Scholar
    • Export Citation
  • 3

    Hart RAPrendergast MA: Spine surgery for lumbar degenerative disease in elderly and osteoporotic patients. Instr Course Lect 56:2572722007

    • Search Google Scholar
    • Export Citation
  • 4

    Holmes CAIshida WElder BDLo SLChen YAKim E: The effects of high-dose parathyroid hormone treatment on fusion outcomes in a rabbit model of posterolateral lumbar spinal fusion alone and in combination with bone morphogenetic protein 2 treatment. World Neurosurg 115:e366e3742018

    • Search Google Scholar
    • Export Citation
  • 5

    Kleerekoper MGreenspan SLLewiecki EMMiller PDKendler DLMaricic M: Assessing the effects of teriparatide treatment on bone mineral density, bone microarchitecture, and bone strength. J Bone Joint Surg Am 96:e902014

    • Search Google Scholar
    • Export Citation
  • 6

    Lee SChung CKOh SHPark SB: Correlation between bone mineral density measured by dual-energy x-ray absorptiometry and Hounsfield units measured by diagnostic CT in lumbar spine. J Korean Neurosurg Soc 54:3843892013

    • Search Google Scholar
    • Export Citation
  • 7

    Marshall DJohnell OWedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:125412591996

    • Search Google Scholar
    • Export Citation
  • 8

    McClung MRSan Martin JMiller PDCivitelli RBandeira FOmizo M: Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:176217682005

    • Search Google Scholar
    • Export Citation
  • 9

    Meredith DSSchreiber JJTaher FCammisa FP JrGirardi FP: Lower preoperative Hounsfield unit measurements are associated with adjacent segment fracture after spinal fusion. Spine (Phila Pa 1976) 38:4154182013

    • Search Google Scholar
    • Export Citation
  • 10

    Miyauchi AMatsumoto TSugimoto TTsujimoto MWarner MRNakamura T: Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:4935022010

    • Search Google Scholar
    • Export Citation
  • 11

    Obermayer-Pietsch BMMarin FMcCloskey EVHadji PFarrerons JBoonen S: Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23:159116002008

    • Search Google Scholar
    • Export Citation
  • 12

    Paggiosi MAYang LBlackwell DWalsh JSMcCloskey EPeel N: Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study. Osteoporos Int 29:136713782018

    • Search Google Scholar
    • Export Citation
  • 13

    Saag KGAgnusdei DHans DKohlmeier LAKrohn KDLeib ES: Trabecular bone score in patients with chronic glucocorticoid therapy-induced osteoporosis treated with alendronate or teriparatide. Arthritis Rheumatol 68:212221282016

    • Search Google Scholar
    • Export Citation
  • 14

    Schreiber JJAnderson PARosas HGBuchholz ALAu AG: Hounsfield units for assessing bone mineral density and strength: a tool for osteoporosis management. J Bone Joint Surg Am 93:105710632011

    • Search Google Scholar
    • Export Citation
  • 15

    Schreiber JJHughes APTaher FGirardi FP: An association can be found between Hounsfield units and success of lumbar spine fusion. HSS J 10:25292014

    • Search Google Scholar
    • Export Citation
  • 16

    Senn CGünther BPopp AWPerrelet RHans DLippuner K: Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos Int 25:194519512014

    • Search Google Scholar
    • Export Citation
  • 17

    Unnanuntana AGladnick BPDonnelly ELane JM: The assessment of fracture risk. J Bone Joint Surg Am 92:7437532010

TrendMD
Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 155 155 52
Full Text Views 41 41 14
PDF Downloads 25 25 5
EPUB Downloads 0 0 0
PubMed
Google Scholar